Cancer Research UK called it “the biggest leap forward in decades” for pancreatic cancer patients.

The charity’s Dr Sam Godfrey told BBC News that the results were incredibly exciting. “What this new drug has done is it’s found a way of drugging the undruggable.

“We are finally seeing progress in pancreatic cancer which is so long overdue.”

Pancreatic cancer is notoriously hard to treat and has the lowest survival rate of all common cancers in the UK.

Although chemotherapy can shrink tumours a bit, the cancer often grows again.

Most patients with advanced disease survive months, not years.

Doctors hope the new treatment might offer patients more time, even if it cannot stop cancers for good.

The trial followed patients for a year and a half, on average, and some did not see their cancer return during this time.

Longer studies are needed to understand if any of these cancers can be put into remission and for how long.

In the trial:

  • tumours stopped growing in 90% of patients

  • just over 60% of patients saw their tumours shrink or disappear

  • for around 8% of patients, or one in 12, tumours became undetectable on CT scans